# Renadyl

### WWW.RENADYL.COM WWW.KIBOWBIOTECH.COM

## **Two Decades of Research Have Shown**

RENADYL HELPS IMPROVE KIDNEY FUNCTION BY REDUCING UREMIC TOXINS





Renadyl<sup>™</sup> is a patented, proprietary kidney health supplement which modulates the gut microbiome to support healthy BUN and creatinine levels, by reducing nitrogenous waste in the bowel and restoring healthy gut flora.

Made in USA Top Rated Patented

## Renadyl™ is a blend of S. thermophilus (KB 19), L. acidophilus (KB27) and B. longum (KB31) strains of probiotic bacteria.

Year	2013	2015	2017*		
Results of Three Consecutive Biennial Customer Survey					
Number of Surveys Sent	998	834	600		
Number of Respondents	147 (14.7%)	168 (20.1%)	214 (35.6%)		
Breakdown of Respondents					
Respondents in ESRD (%)	17%	17%	21%		
Respondents in CKD III and IV (%)	57%	58%	73%		
Respondents indicating Renadyl improved quality of life (%)	73%	72%	88%		
GFR Results					
Average change in GFR since taking Renadyl	_**	_**	3.5 mL/min/1.73m <sup>2</sup>		

KIBOW®BIOTECH

\* Since the previous 2013 and 2015 survey, the Renadyl formulation has been improved

\*\* GFR information was not ascertained in 2013 or 2015 in compliance with HIPPA regulations, 2017 GFR data is selfreported by the survey respondents.

DISCLAIMER: These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. All products are manufactured in USA.


Kibow Biotech, Inc. (USA), 4781 West Chester Pike, Newtown Square, PA, 19073, USA P. +1.888.271.2560 (US), P. +1.610.353.5130 (Intl.), F. +1.610.353.5110, Email: info@kibowbiotech.com

## FROM CONCEPT TO REALITY ENTERIC DIALYSIS® IS WORKING FOR PATIENTS!

# Multi-year study supports findings that Renadyl use is associated with\*:

- Stabilized or increased GFR
- Reduced uremic toxins
- Reduced inflammation (CRP)
- Improved quality of life in all stages of CKD, resulting in better user-reported outcomes for dialysis patients

## **Renadyl**<sup>™</sup> impact on GFR



- Average GFR increase of 3.5 mL/min
- 88% of survey respondents indicated that Renadyl improved quality of life
- Alleviates dysbiosis via modulation of the gut microbiome
- Proprietary and patented kidney health supplement utilizing a unique formulation of Probiotics and Prebiotics

No prescription needed, and a safe option for your patients.

## VISIT US AT ASN BOOTH #1011 TO LEARN MORE

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent disease. \*Data on file, Kibow Biotech. 'Average decrease in GFR per year: 4.42 mL/min. **Reference: 1.** Tsai CW, Ting IW, Yeh HC, Kuo CC. Longitudinal change in estimated GFR among CKD patients: A 10-year follow-up study of an integrated kidney disease care program in Taiwan. *PLoS One.* 2017;12(4):e0173843 Published online April 5, 2017. doi:10.1371/journal.pone.0173843.

ER POTENCY FROM

KIBOW

Renady

HELPS MAINTAIN EALTHY KIDNEY FUNCTION

Kibow and Enteric Dialysis are registered trademarks and Renadyl is a trademark of Kibow Biotech, Inc. © 2017 Kibow Biotech, Inc. All rights reserved. 17744



4781 West Chester Pike, Newtown Square, PA 19073 USA www.kibowbiotech.com



### **Possible Improvements in GFR of CKD Patients with Renadyl<sup>™</sup>-3<sup>rd</sup> Biennial Survey**

COMPANY EXHIBIT POSTER N Ranganathan <sup>1</sup>, P Ranganathan <sup>1</sup>, K Hanlon <sup>1</sup>, A Irvin<sup>1</sup> U Vyas <sup>1</sup>, A Weinberg <sup>2</sup>, E.A Friedman <sup>3</sup>

ASN Nov 2-4, 2017 New Orleans, LA

<sup>1</sup> Kibow Biotech Inc., Newtown Square, PA, USA; <sup>2</sup>Mount Sinai School of Medicine, New York, NY, USA, <sup>3</sup>Downstate Medical Center, State University of New York (SUNY), Brooklyn, NY, USA

#### INTRODUCTION

Probiotics and Prebiotics are seeing wide application in gut related disorders like digestion and immunity. Recent scientific advances have revealed the role of the gut microbiome in various diseases beyond gut health like asthma / allergies, colon cancer / biliary disease, obesity, inflammatory bowel disease(IBD), hypertension / peripheral vascular disease and also the gut-brain axis in autism, anxiety and Parkinson's disease. A prime example of this trend is the burgeoning field of research on gut microbiome and kidney, the gut-kidney connection, as well as on various approaches to its modulation using probiotics and prebiotics. We at Kibow Biotech have been working over two decades on developing a probiotic dietary supplement (GUT-KIDNEY AXIS: KIBOW'S CONCEPT of "ENTERIC DIALYSIS", USING THE BOWEL AS A SURROGATE KIDNEY) for the removal of uremic toxins in renal failure patients. The formulation has been studied in a small number of randomized clinical trials for a pharmaceutical like validation. Kibow Biotech's "Enteric Dialvsis®" concept based off of the modulation of the gut microbiome to maintain healthy kidney function has proved to be helpful in many of those suffering from CKD. Kibow's product "Renadyl™" has been available since 2010 and is continually being studied to assess just how effective it is. A short survey given to 600 Renadyl customers was distributed to ascertain how their GFR changed, and the impact on their quality of life (QoL) after adding the dietary supplement Renadyl<sup>™</sup> into their standard care of therapy.

#### **METHODS**

"Renadyl<sup>™</sup>," a synbiotic dietary supplement was assessed in its ability to maintain healthy kidney function (stabilize GFR), and ability to improve quality of life. A survey was distributed to 600 customers asking for GFR when they began taking Renadyl, and at their most recent doctors visit, as well as age, race, ethnicity, and if Renadyl<sup>™</sup> had improved their overall quality of life or not. Statistical analyses were performed on the GFR data to estimate Renadyl's<sup>™</sup> impact on GFR, and quality of life. This was done independently analyzed by Alan Weinberg using SAS. Of the 600 surveys sent, 214 (35%) responses were received.

#### **RESULTS**

35% (214) of the customers responded.

A) Efficacy as per NKF/FDA guidelines and our data analysis


Year	Average Progression of CKD (mL/min/1.73 m <sup>2</sup> )	NKF/FDA 40% (Preferred) Endpoint Drug Progression (mL/min/1.73 m <sup>2</sup> )	Renadyl GFR (mL/min/1.73 m <sup>2</sup> )
1	30	30	30
2	25.6	27.4	32.9
3	21.2	24.8	35.8

#### RESULTS

B) Efficacy of Renadyl-GFR before and after Renadyl usage

Variable	N	Mean	Std Dev	Minimum	Maximum
gfr1	150	30.521333	17.244093	4	100
gfr2	150	34.074733	20.02078	5	106
diff	150	3.5534	13.240966	-40	65
Yearchange	141	2.9038151	8.4003586	-16	42.222222

#### C) Renadyl -Possible improvements in GFR



#### D) Renadyl Satisfaction-QoL

Quality of Life (QoL) by sex				
Qol	Sex			
Frequency	F	м	Total	
Percent (%)	Г	IVI	TOtal	
No	6	18	24	
% of M/F	3	9	12	
% No by M/F	7.23	15.38		
Yes	77	99	176	
% of M/F	38.5	49.5	88	
% Yes by M/F	92.77	84.62		
Total	83	117	200	
Percent M/F	41.5	58.5	100	
Frequency Missing = 14				


#### **CONCLUSIONS**

Chronic kidney disease is generally recognized as a degenerative process. However, with over 4,000 customers we sought feedback from 600 of them to assess the impact of Renadyl<sup>™</sup> usage over an average of 2.05 years. The longest using participant used the product for 7 years, the shortest for 6 months. With the ability to stabilize and improve GFR, it may be possible to delay the progression of kidney function decline at all stages. Improving quality of life in 88% of participants certainly signifies the advantages of using Renadyl<sup>™</sup> in patients with compromised renal function worldwide.


# Renadyl

### WWW.RENADYL.COM WWW.KIBOWBIOTECH.COM

## **Three Cumulative Clinical Trial Findings**



## **Mechanism Of Action – The Gut Kidney Connection**



Kibow Biotech, Inc. (USA), 4781 West Chester Pike, Newtown Square, PA, 19073, USA P. +1.888.271.2560 (US), P. +1.610.353.5130 (Intl.), F. +1.610.353.5110, Email: info@kibowbiotech.com